Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been assigned an average recommendation of “Hold” from the five ratings firms that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $3.33.

A number of analysts have commented on the company. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. StockNews.com assumed coverage on shares of Syros Pharmaceuticals in a research report on Friday, January 24th. They issued a “sell” rating for the company. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th.

Insider Buying and Selling

In other news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares in the company, valued at $11,088.90. The trade was a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 12.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

A hedge fund recently bought a new stake in Syros Pharmaceuticals stock. GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,905 shares of the company’s stock, valued at approximately $34,000. GSA Capital Partners LLP owned 0.06% of Syros Pharmaceuticals at the end of the most recent reporting period. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Price Performance

Shares of SYRS opened at $0.19 on Monday. The company has a market capitalization of $5.12 million, a PE ratio of -0.06 and a beta of 1.31. Syros Pharmaceuticals has a one year low of $0.18 and a one year high of $7.96. The company’s fifty day moving average price is $0.23 and its 200 day moving average price is $1.87.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period last year, the firm posted ($1.35) EPS. Analysts anticipate that Syros Pharmaceuticals will post -2.94 earnings per share for the current year.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.